HHS OIG recommendations · Department of Health and Human Services
Food and Drug Administration
13 open and 85 closed recommendations from HHS Office of Inspector General name this office as responsible, in the publisher's own file.
Source: HHS OIG Recommendation Tracker, official export read .
13openpublisher's status
85closedall closed statuses
4open five years or morecounted from the issue date
Jan 9, 2009oldest open, issued
| Publisher's status | Recommendations |
|---|---|
| Closed Implemented | 78 |
| Open Unimplemented | 13 |
| Closed Unimplemented | 4 |
| Closed Acceptable Alternative | 3 |
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Open recommendations, oldest first
- FDA should require that sponsors submit financial information for clinical investigators as part of the pretrial application process.HHS OIG 09-E-05-018.07 · issued Jan 9, 2009Open Unimplemented
- FDA should consider seeking statutory authority to impose civil penalties through administrative proceedings against facilities that do not voluntarily comply with statutory and regulatory…HHS OIG 10-E-02-029.05 · issued Apr 5, 2010Open Unimplemented
- FDA should seek statutory authority to impose civil monetary penalties on companies that do not comply with registration requirements.HHS OIG 13-E-01-002.02 · issued Oct 2, 2012Open Unimplemented
- FDA should improve the timeliness of FDA's actions, including warning letters, so that facilities do not continue to operate under harmful conditions.HHS OIG 17-E-02-042.03 · issued Sep 25, 2017Open Unimplemented
- We recommend that the FDA automate both the tracking of awards assigned to contract closeout staff for closeout and the process of sending closeout documents to the contractor and COR.HHS OIG 22-A-03-023.02 · issued Dec 16, 2021Open Unimplemented
- We recommend that the Food and Drug Administration conduct an analysis of the workloads of individuals responsible for: (1) determining final classification, (2) issuing warning letters,…HHS OIG 22-A-01-069.03 · issued Jun 24, 2022Open Unimplemented
- FDA should complete its rulemaking on non-face-to-face sales of tobacco products, as required by the Tobacco Control Act.HHS OIG 23-E-01-005.02 · issued Nov 29, 2022Open Unimplemented
- FDA should publish information and performance data on its oversight of online tobacco retailers.HHS OIG 23-E-01-005.04 · issued Nov 29, 2022Open Unimplemented
- We recommend that the Food and Drug Administration design and implement policies and procedures specific to the use of its FDA-required infant formula recall authority.HHS OIG 24-A-01-080.07 · issued Jun 10, 2024Open Unimplemented
- FDA should increase the number of facilities inspected each year and ensure that all facilities are inspected within the required timeframes.HHS OIG 25-E-02-031.01 · issued May 30, 2025Open Unimplemented
- FDA should improve methods for identifying facilities that are not in operation to make better use of resources.HHS OIG 25-E-02-031.02 · issued May 30, 2025Open Unimplemented
- FDA should assess reasons for the decrease in number of facilities inspected by FDA with significant violations and take action as appropriate.HHS OIG 25-E-02-031.03 · issued May 30, 2025Open Unimplemented
- FDA should conduct timely followup inspections of facilities with significant violations.HHS OIG 25-E-02-031.04 · issued May 30, 2025Open Unimplemented
Closed recommendations, most recently closed first
- FDA should define specific factors that would require FDA's accelerated approval council to advise on certain drug applications.HHS OIG 25-E-01-010.01 · issued Jan 7, 2025 · closed May 18, 2026Closed Unimplemented
- FDA should take steps to ensure appropriate documentation of meetings with sponsors in drug approval administrative files.HHS OIG 25-E-01-010.02 · issued Jan 7, 2025 · closed May 18, 2026Closed Implemented
- We recommend that the Food and Drug Administration identify and implement additional ways to improve the timeliness of its foreign for-cause drug inspection process.HHS OIG 22-A-01-069.01 · issued Jun 24, 2022 · closed Apr 3, 2026Closed Implemented
- We recommend that the Food and Drug Administration develop policies and procedures that FDA can use during future public health emergencies to identify how and when it is necessary to…HHS OIG 24-A-01-080.06 · issued Jun 10, 2024 · closed Apr 3, 2026Closed Implemented
- FDA should assess and, as appropriate, revise FDA guidance for test Emergency Use Authorization (EUA) submissions.HHS OIG 22-E-01-034.01 · issued Sep 16, 2022 · closed Mar 30, 2026Closed Implemented
- FDA should work with Federal partners to implement lessons learned about a national testing strategy outside the Emergency Use Authorization (EUA) process.HHS OIG 22-E-01-034.06 · issued Sep 16, 2022 · closed Mar 30, 2026Closed Implemented
- FDA work with the Program Support Center to obtain from PRISM recurring reports used to facilitate contract closeout.HHS OIG 22-A-03-023.06 · issued Dec 16, 2021 · closed Mar 12, 2026Closed Implemented
- FDA should collect data to support process and outcome measures for its oversight of online tobacco retailers.HHS OIG 23-E-01-005.03 · issued Nov 29, 2022 · closed Mar 10, 2026Closed Implemented
- We recommend that the Food and Drug Administration implement policies and procedures to ensure that lead investigators assigned to inspections have completed the Level 1 Investigator…HHS OIG 22-A-01-069.04 · issued Jun 24, 2022 · closed Nov 13, 2025Closed Implemented
- FDA should develop a suite of Emergency Use Authorization (EUA) templates for future emergencies involving novel pathogens.HHS OIG 22-E-01-034.02 · issued Sep 16, 2022 · closed Sep 29, 2025Closed Unimplemented
- FDA should expand the Center for Devices and Radiological Health's existing device-tracking platform to facilitate Emergency Use Authorization (EUA) submission and monitoring.HHS OIG 22-E-01-034.03 · issued Sep 16, 2022 · closed Sep 29, 2025Closed Unimplemented
- We recommend that the Food and Drug Administration implement policies and procedures that facilitate reporting consumer complaints in real time to investigators onsite when an active…HHS OIG 24-A-01-080.03 · issued Jun 10, 2024 · closed Sep 16, 2025Closed Implemented
- We recommend that the Food and Drug Administration prioritize maintaining the NCCC's continuity of operations by cross-training staff on whistleblower policies and procedures and NCCC…HHS OIG 24-A-01-080.01 · issued Jun 10, 2024 · closed Apr 28, 2025Closed Implemented
- FDA should expand and improve resources for test developers on the Emergency Use Authorization (EUA) process.HHS OIG 22-E-01-034.04 · issued Sep 16, 2022 · closed Apr 7, 2025Closed Implemented
- FDA should seek legislative authority to enforce FDA assessment plans.HHS OIG 13-E-04-029.06 · issued Feb 12, 2013 · closed Mar 31, 2025Closed Implemented
- FDA should ensure that assessment reviews are timely.HHS OIG 13-E-04-029.07 · issued Feb 12, 2013 · closed Mar 31, 2025Closed Implemented
- FDA should enhance its Risk Evaluation and Mitigation Strategy (REMS) assessment review process.HHS OIG 20-E-01-044.03 · issued Sep 25, 2020 · closed Mar 31, 2025Closed Implemented
- FDA should seek additional authority to ensure that manufacturers are held accountable when appropriate.HHS OIG 20-E-01-044.04 · issued Sep 25, 2020 · closed Mar 31, 2025Closed Implemented
- FDA should give greater weight to retailers' past noncompliance when taking enforcement actions against retailers with histories of violations.HHS OIG 23-E-01-040.01 · issued Sep 18, 2023 · closed Mar 31, 2025Closed Implemented
- FDA should determine whether variation in inspection activity on the basis of neighborhoods' socioeconomic status is appropriate and the extent to which it is meeting FDA's objective for…HHS OIG 23-E-01-040.02 · issued Sep 18, 2023 · closed Mar 31, 2025Closed Implemented
- FDA should collaborate with the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) on oversight of online tobacco retailers.HHS OIG 23-E-01-005.01 · issued Nov 29, 2022 · closed Mar 12, 2025Closed Implemented
- We recommend that the Food and Drug Administration consistently implement its existing policies and procedures and use existing checklists to ensure that contracting officer's…HHS OIG 23-A-18-034.01 · issued Jan 13, 2023 · closed Mar 11, 2025Closed Implemented
- We recommend that the Center for Tobacco Products assess the PMTA review process and develop an action plan to resolve the backlog of PMTA applications and achieve compliance with the…HHS OIG 24-A-06-014.02 · issued Nov 8, 2023 · closed Mar 7, 2025Closed Implemented
- We recommend that the Food and Drug Administration consistently implement its existing policies and procedures and use existing checklists to ensure that the appropriate contracting…HHS OIG 23-A-18-034.03 · issued Jan 13, 2023 · closed Mar 4, 2025Closed Implemented
- We recommend that the Food and Drug Administration evaluate internal procedures and documents for key contracting decisions and activities to verify that all supporting contract documents…HHS OIG 23-A-18-034.04 · issued Jan 13, 2023 · closed Mar 4, 2025Closed Implemented
- We recommend that the Food and Drug Administration should consistently implement its existing policies and procedures and use existing checklists to ensure that the appropriate contracting…HHS OIG 23-A-18-034.06 · issued Jan 13, 2023 · closed Mar 4, 2025Closed Implemented
- We recommend that the Food and Drug Administration develop and implement policies and procedures requiring periodic reporting (e.g.,monthly reporting) to senior leadership on the status of…HHS OIG 24-A-01-080.02 · issued Jun 10, 2024 · closed Jan 30, 2025Closed Implemented
- We recommend that the Food and Drug Administration strengthen the QFC process to identify data entry inaccuracies.HHS OIG 24-A-01-080.04 · issued Jun 10, 2024 · closed Jan 30, 2025Closed Implemented
- We recommend that the Food and Drug Administration continue to seek legislative authority to require infant formula manufacturers to notify and provide the bacterial isolate to FDA every…HHS OIG 24-A-01-080.09 · issued Jun 10, 2024 · closed Jan 30, 2025Closed Implemented
- We recommend that the Food and Drug Administration formalize written policies and procedures that either require that the CAERS coordinator forward all reports that originate in CAERS to…HHS OIG 24-A-01-080.05 · issued Jun 10, 2024 · closed Dec 19, 2024Closed Acceptable Alternative
- We recommend that the Food and Drug Administration amend the language on the CAERS adverse event report form to emphasize the importance of including the lot number to encourage the public…HHS OIG 24-A-01-080.08 · issued Jun 10, 2024 · closed Dec 19, 2024Closed Implemented
- We recommend that the Food and Drug Administration ensure that supervisors review investigators' qualifications and document that they meet applicable training requirements when the…HHS OIG 22-A-01-069.05 · issued Jun 24, 2022 · closed May 20, 2024Closed Implemented
- We recommend that the Food and Drug Administration review the training records of the lead investigators that were outside the scope of the audit to verify that documentation supports…HHS OIG 22-A-01-069.06 · issued Jun 24, 2022 · closed May 20, 2024Closed Implemented
- We recommend that the Center for Tobacco Products work with OPM to obtain direct-hire authority to assist CTP in reaching its FTE goal.HHS OIG 24-A-06-014.01 · issued Nov 8, 2023 · closed Apr 26, 2024Closed Implemented
- FDA should use the new TIRF Risk Evaluation and Mitigation Strategy (REMS) patient registry to monitor for known areas of risk, such as inappropriate conversions and off-label prescribing.HHS OIG 20-E-01-044.01 · issued Sep 25, 2020 · closed Apr 17, 2024Closed Implemented
- FDA should strengthen the Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics (the successor to ER/LA opioids) by requiring prescriber training.HHS OIG 20-E-01-044.02 · issued Sep 25, 2020 · closed Apr 17, 2024Closed Acceptable Alternative
- We recommend that the Food and Drug Administration prepare and submit timely Annual Competition Advocate Reports (ACARS) to HHS in accordance with the requirements of FAR 6.502(b)(2) and…HHS OIG 23-A-18-034.05 · issued Jan 13, 2023 · closed Apr 8, 2024Closed Implemented
- FDA should establish formal communication channels between FDA and the lab community, to be used in emergencies that require testing.HHS OIG 22-E-01-034.05 · issued Sep 16, 2022 · closed Apr 2, 2024Closed Implemented
- FDA should provide a standardized form for Annual Status Reports (ASRs), ensure that they are complete, and require sponsors to submit them electronically.HHS OIG 16-E-01-035.01 · issued Jul 20, 2016 · closed Mar 28, 2024Closed Implemented
- FDA should build capacity in the Document Archiving, Reporting, and Regulatory Tracking System (DARRTS) to support postmarketing requirements (PMR) oversight.HHS OIG 16-E-01-035.02 · issued Jul 20, 2016 · closed Mar 28, 2024Closed Implemented
- We recommend that the Food and Drug Administration consider streamlining the process for writing and reviewing EIRs to minimize potential delays due to unexpected events.HHS OIG 22-A-01-069.02 · issued Jun 24, 2022 · closed Mar 12, 2024Closed Implemented
- We recommend that the Food and Drug Administration deobligate $88,152 in contract funding and close the six contracts that remained open but eligible for closeout as of June 15, 2021.HHS OIG 22-A-03-023.01 · issued Dec 16, 2021 · closed Mar 11, 2024Closed Implemented
- We recommend that the FDA add language to the contract awards to require that contractors specify when an invoice is the final contract invoice.HHS OIG 22-A-03-023.03 · issued Dec 16, 2021 · closed Mar 11, 2024Closed Implemented
- We recommend that the FDA require contracting officers and CORs to notify contract closeout specialists in a timely manner when a contract is physically complete.HHS OIG 22-A-03-023.04 · issued Dec 16, 2021 · closed Mar 11, 2024Closed Implemented
- FDA require that CORs communicate a change in COR to the contracting officer before the COR leaves the position.HHS OIG 22-A-03-023.05 · issued Dec 16, 2021 · closed Mar 11, 2024Closed Implemented
- We recommend that the Food and Drug Administration consistently implement its existing policies and procedures and use existing checklists to ensure that contractor performance assessments…HHS OIG 23-A-18-034.02 · issued Jan 13, 2023 · closed Aug 14, 2023Closed Implemented
- FDA should seek legislative authority to include information about a drug product�s complete physical path through the supply chain on drug product tracing information.HHS OIG 20-E-05-009.03 · issued Feb 21, 2020 · closed Mar 10, 2023Closed Acceptable Alternative
- FDA should provide technical assistance regarding exempt products.HHS OIG 17-E-05-038.02 · issued Sep 12, 2017 · closed Jun 24, 2022Closed Implemented
- We recommend that FDA establish performance measures for the amount of time between the date FDA learns of a potentially hazardous product and the date a firm initiates a voluntary recall,…HHS OIG 18-A-01-040.11 · issued Dec 22, 2017 · closed May 27, 2022Closed Implemented
- FDA should require standardized electronic clinical trial data and create an internal database.HHS OIG 10-E-01-040.01 · issued Jun 22, 2010 · closed Apr 5, 2022Closed Implemented
- FDA should provide educational outreach to trading partners about required drug product tracing information and data standardization guidelines.HHS OIG 20-E-05-009.02 · issued Feb 21, 2020 · closed Apr 5, 2022Closed Implemented
- We recommend that FDA ensure, through its recall audit plan, that audit checks are issued at the level specified in the FDA audit program.HHS OIG 18-A-01-040.04 · issued Dec 22, 2017 · closed Nov 3, 2021Closed Implemented
- We recommend that FDA develop a policy for defining and a procedure for identifying retrospectively the date that FDA learns of a potentially hazardous product and consider adding a field…HHS OIG 18-A-01-040.10 · issued Dec 22, 2017 · closed Nov 3, 2021Closed Implemented
- We recommend that the Food and Drug Administration finalize and implement formal policies and procedures for resolving program and IT audit recommendations, similar to the Framework that…HHS OIG 19-A-07-134.01 · issued Aug 20, 2019 · closed May 5, 2021Closed Implemented
- We recommend that the Food and Drug Administration promptly resolve the 32 outstanding audit recommendations (166 that were past due as of September 30, 2016, less 134 resolved after the…HHS OIG 19-A-07-134.02 · issued Aug 20, 2019 · closed May 5, 2021Closed Implemented
- We recommend that the Food and Drug Administration reconcile each month the OIG stewardship reports (or the HHS electronic Single Audit recommendation listing for audits processed on or…HHS OIG 19-A-07-134.03 · issued Aug 20, 2019 · closed May 5, 2021Closed Implemented
- FDA should further communicate to hospitals the importance of obtaining NPS compounded drugs from outsourcing facilities.HHS OIG 19-E-01-018.01 · issued Jun 7, 2019 · closed Apr 5, 2021Closed Implemented
- FDA should take appropriate followup action with the unregistered compounding facilities on the list that we provided.HHS OIG 19-E-01-018.02 · issued Jun 7, 2019 · closed Apr 5, 2021Closed Implemented
- We recommend that FDA update its registered entities' security plans to include procedures for notifying FSAP if a select agent shipment is not received within 48 hours after the expected…HHS OIG 19-A-03-106.01 · issued Jun 26, 2019 · closed Feb 25, 2021Closed Implemented
- We recommend that FDA update its registered entities' security plans to include procedures for notifying FSAP if a select agent package is received damaged to the extent that a release of…HHS OIG 19-A-03-106.02 · issued Jun 26, 2019 · closed Feb 25, 2021Closed Implemented
- We recommend that FDA update its registered entities' security plans to include procedures for notifying FSAP if a select agent shipment will not be completed within 30 calendar days after…HHS OIG 19-A-03-106.03 · issued Jun 26, 2019 · closed Feb 25, 2021Closed Implemented
- We recommend that FDA update its registered entities' security plans to include procedures for notifying FSAP if a select agent transfer authorization becomes void because the facts…HHS OIG 19-A-03-106.04 · issued Jun 26, 2019 · closed Feb 25, 2021Closed Implemented
- We recommend that FDA ensure that its registered entities verify and maintain documentation to assure that employees who are required to have select agent training understand the training…HHS OIG 19-A-03-106.05 · issued Jun 26, 2019 · closed Feb 25, 2021Closed Implemented
- We recommend that FDA Update its policies for shipping inactivated select agents to require that its registered entities record a description of the viability testing protocol used, the…HHS OIG 19-A-03-106.06 · issued Jun 26, 2019 · closed Feb 25, 2021Closed Implemented
- We recommend that FDA establish written procedures and practices for securely sharing sensitive information about cybersecurity events with key stakeholders who have a �need to know.�HHS OIG 19-A-18-013.02 · issued Oct 29, 2018 · closed Jan 20, 2021Closed Implemented
- FDA should follow up with the wholesale distributor that did not provide tracing information to OIG.HHS OIG 20-E-05-009.01 · issued Feb 21, 2020 · closed Aug 28, 2020Closed Implemented
- We recommend that FDA implement procedures to request status reports at the initiation of the recall and, through its recall audit plan, ensure FDA monitoring district offices follow up…HHS OIG 18-A-01-040.09 · issued Dec 22, 2017 · closed Jul 6, 2020Closed Implemented
- We recommend that FDA develop procedures to determine whether a reconciliation of distribution lists to shipping records is necessary to ensure that FDA uses complete and accurate…HHS OIG 18-A-01-040.05 · issued Dec 22, 2017 · closed Mar 3, 2020Closed Implemented
- We recommend that FDA increase the use of third-party audit checks through its recall strategic plan.HHS OIG 18-A-01-040.06 · issued Dec 22, 2017 · closed Mar 3, 2020Closed Implemented
- We recommend that FDA continually assess the cybersecurity risks to medical devices and update, as appropriate, its plans and strategies.HHS OIG 19-A-18-013.01 · issued Oct 29, 2018 · closed Feb 25, 2020Closed Implemented
- We recommend that FDA enter into a formal agreement with Federal agency partners, namely the DHS Industrial Control Systems Cyber Emergency Response Team, establishing roles and…HHS OIG 19-A-18-013.03 · issued Oct 29, 2018 · closed Feb 25, 2020Closed Implemented
- We recommend that FDA ensure the establishment and maintenance of procedures for handling recalls of medical devices vulnerable to cybersecurity vulnerabilities, exploitations, and threats.HHS OIG 19-A-18-013.04 · issued Oct 29, 2018 · closed Feb 25, 2020Closed Implemented
- FDA should promote the use of presubmission meetings to address cybersecurity-related questions.HHS OIG 18-E-09-036.01 · issued Sep 10, 2018 · closed Feb 21, 2020Closed Implemented
- FDA should include cybersecurity documentation as a criterion in FDA�s Refuse-to-Accept checklists.HHS OIG 18-E-09-036.02 · issued Sep 10, 2018 · closed Feb 21, 2020Closed Implemented
- FDA should include cybersecurity as an element in the Smart template.HHS OIG 18-E-09-036.03 · issued Sep 10, 2018 · closed Feb 21, 2020Closed Implemented
- FDA should provide educational outreach to dispensers about the Drug Supply Chain Security Act (DSCSA) requirements for receiving drug product tracing information.HHS OIG 18-E-05-012.01 · issued Mar 26, 2018 · closed Feb 11, 2020Closed Implemented
- We recommend that FDA establish set timeframes, through its SCORE initiative, for (1) FDA to discuss the possibility of a voluntary recall with a firm and (2) FDA to initiate use of its…HHS OIG 18-A-01-040.01 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- We recommend that FDA include in its recall audit plan a step to monitor when the recall alert was submitted to the RES in accordance with current FDA alert submission procedures and, if…HHS OIG 18-A-01-040.02 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- We recommend that FDA finalize its interim mandatory recall procedures and consider issuing guidance for FDA staff on those factors that staff should consider when determining whether…HHS OIG 18-A-01-040.03 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- We recommend that FDA ensure, through its recall audit plan, that FDA district offices conducting audit checks follow procedures by completing audit check status updates and providing…HHS OIG 18-A-01-040.07 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- We recommend that FDA improve audit check tracking and monitoring using the RES or another FDA system.HHS OIG 18-A-01-040.08 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- We recommend that FDA clarify the definition of �recall initiation date� in its policies and procedures and ensure a consistent understanding of �recall initiation date� among recall…HHS OIG 18-A-01-040.12 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- We recommend that FDA develop and implement a data quality assurance process, through its recall audit plan, to ensure that the RES contains accurate information.HHS OIG 18-A-01-040.13 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- We recommend that FDA consider the results of our review when implementing its recent SCORE initiative.HHS OIG 18-A-01-040.14 · issued Dec 22, 2017 · closed Aug 8, 2019Closed Implemented
- FDA should seek explicit statutory authority to review substantiation for structure/function claims to determine whether claims are truthful and not misleading.HHS OIG 13-E-01-001.01 · issued Oct 2, 2012 · closed May 31, 2017Closed Unimplemented
Follow or embed this office
Every change the publisher makes to one of this office's recommendations is added to a feed: Food and Drug Administration changes (Atom).